Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma

This is a single arm, open label, multicenter study phase 2 study of pembrolizumab and brentuximab in subjects with relapsed/refractory CD30 positive T-cell lymphoma (including peripheral T-cell lymphoma and cutaneous T-cell lymphoma) who have received at least one prior therapy. We hypothesize that this combination is effective and will produce an overall response rate of \~55%. Pembrolizumab and brentuximab will be administered for 16 cycles in subjects with responsive disease. Pembrolizumab will be continued for an additional 19 cycles (total 35 cycles). Response assessments will occur at p

Trial Details

NCT ID
NCT05313243
Phase
PHASE2
Sponsor
Yale University
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Brentuximab vedotin
  • Pembrolizumab
Locations (sample)
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Boston, Massachusetts, United States|42.35843,-71.05977

Key Eligibility Criteria

  • Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of T-cell …
  • The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • Histologically confirmed T-cell Non-Hodgkin lymphoma (T-NHL), including:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →